SCHEMBL27162872

SCHEMBL27162872

O=S(=O)(c1ccc(N2CCOCC2)nc1)N1CCCC2(CCN(Cc3ccncc3)CC2)C1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.53
▸ SMN1; SMN2 Q16637 5/20 0.52
▸ CYP3A4 P08684 11/20 0.52
▸ CYP2D6 P10635 11/20 0.52
▸ CYP2C9 P11712 8/20 0.52
▸ TSHR P16473 7/20 0.52
▸ CYP1A2 P05177 6/20 0.52
▸ CYP2C19 P33261 6/20 0.52
▸ USP2 O75604 4/20 0.52
▸ LMNA P02545 1/20 0.50
▸ TP53 P04637 1/20 0.48
▸ GAA P10253 3/20 0.46
▸ KDM4E B2RXH2 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30050718 1.00 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2CYP3A4CYP2D6CYP2C9
SCHEMBL27161993 0.92 CYP3A4 (0.58) ALDH1A1SMN1; SMN2CYP3A4CYP2D6CYP2C9
SCHEMBL30050081 0.92 CYP3A4 (0.58) ALDH1A1SMN1; SMN2CYP3A4CYP2D6CYP2C9
SCHEMBL31097543 0.87 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2CYP3A4CYP2D6CYP2C9
SCHEMBL27162633 0.87 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2CYP3A4CYP2D6CYP2C9
SCHEMBL30050943 0.82 SMN1; SMN2 (0.49) ALDH1A1SMN1; SMN2CYP3A4CYP2D6CYP2C9
SCHEMBL27162174 0.82 SMN1; SMN2 (0.49) ALDH1A1SMN1; SMN2CYP3A4CYP2D6CYP2C9
SCHEMBL30049877 0.82 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2CYP3A4CYP2D6CYP2C9
SCHEMBL27162435 0.82 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2CYP3A4CYP2D6CYP2C9
SCHEMBL30050728 0.81 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands ACONDICIONAMIENTO TARRASENSE (ES) 2024-08-01 — — US claimed
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP claimed
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands ACONDICIONAMIENTO TARRASENSE (ES) 2024-08-01 — — US disclosed
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands SIGMAR1, TMEM97, OPRD1 ALDH1A1 1011/4885SMN1; SMN2 3118/4885CYP3A4 497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback